IDEXX Laboratories, Inc. $IDXX Shares Sold by Pictet Asset Management Holding SA

Key Points

• Pictet Asset Management cut its stake in IDEXX Laboratories by 38.4% in Q4, selling 107,248 shares and leaving it with 172,239 shares worth about $116.6 million.
• IDEXX beat Q4 expectations with $3.08 EPS (vs. $2.93 est.) and revenue up 14.3%, and it set FY2026 guidance of 14.29–14.80 EPS while analysts maintain an average target near $760 with mixed buy/hold ratings.
• Insiders have been active sellers recently — a total of 45,957 shares worth about $29.9 million were sold over the past 90 days — while institutional investors own roughly 87.8% of the stock.

Pictet Asset Management Holding SA lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 38.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 172,239 shares of the company's stock after selling 107,248 shares during the period. Pictet Asset Management Holding SA owned about 0.22% of IDEXX Laboratories worth $116,574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of IDXX. Empowered Funds LLC raised its position in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock valued at $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $265,000. Jump Financial LLC raised its position in IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company's stock valued at $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $164,000. Finally, Sei Investments Co. raised its position in IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company's stock valued at $64,678,000 after purchasing an additional 82,755 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group reduced their price target on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $760.00.

IDEXX Laboratories Trading Up 1.6%

IDXX opened at $574.95 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $427.70 and a one year high of $769.98. The company has a market cap of $45.67 billion, a P/E ratio of 43.99, a PEG ratio of 3.44 and a beta of 1.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The business's 50-day simple moving average is $593.73 and its 200-day simple moving average is $652.77.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the business posted $2.53 EPS. The business's revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.54 EPS for the current fiscal year.

Insider Activity

In related news, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares in the company, valued at $407,345.76. This represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,957 shares of company stock worth $29,862,109 over the last ninety days. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.